Table 1. Baseline characteristics of the 86 advanced HCC patients receiving camrelizumab in combination with apatinib therapy.
| Characteristics | All patients (n=86) |
|---|---|
| Gender, n (%) | |
| Male | 72 (83.7) |
| Female | 14 (16.3) |
| Age (y)Δ | 54.5±12.1 |
| BCLC stage, n (%) | |
| B | 22 (25.6) |
| C | 64 (74.4) |
| Child-Pugh class, n (%) | |
| A | 64 (74.4) |
| B | 22 (25.6) |
| ECOG performance, n (%) | |
| 0 | 1 (1.2) |
| 1 | 54 (62.8) |
| 2 | 31 (36.0) |
| Portal vein tumor thrombus, n (%) | |
| Yes | 40 (46.5) |
| No | 46 (53.5) |
| Extrahepatic metastasis, n (%) | |
| Yes | 20 (23.3) |
| No | 66 (76.7) |
| Tumor number, n (%) | |
| <3 | 39 (45.3) |
| ≥3 | 47 (54.7) |
| Largest tumor diameter (cm) | 7.4 (1.0, 17.8) |
| α-Fetoprotein level, n (%) | |
| <400 ng/mL | 42 (48.8) |
| ≥400 ng/mL | 44 (51.2) |
| ALT (U/L)* | 30.0 (5.0, 216.0) |
| AST (U/L)* | 42.0 (9.0, 231.0) |
| Albumin (g/L)Δ | 37.1±5.3 |
| Total bilirubin (mmol/L)* | 13.6 (5.3, 78.7) |
| PLT (109/L)* | 158.0 (35.0, 556.0) |
| PT (s)* | 11.6 (9.7, 142.0) |
| ALBI grade, n (%) | |
| 1 | 43 (50.0) |
| 2 | 37 (43.0) |
| 3 | 6 (7.0) |
| HBV DNA, n (%) | |
| <2,000 IU/mL | 55 (64.0) |
| ≥2,000 IU/mL | 31 (36.0) |
| HBsAg (IU/mL)* | 219.8 (1.71, 7,379.0) |
| HBeAg, n (%) | |
| Positive | 18 (2.9) |
| Negative | 68 (79.1) |
| Anti-viral therapy, n (%) | |
| ETV | 32 (37.2) |
| TDF | 11 (12.8) |
| TAF | 38 (44.2) |
| Others | 5 (5.8) |
Ä, normal distribution (mean ± standard deviation); *, non-normal distribution [median, (minimum, maximum)]. HCC, hepatocellular carcinoma; BCLC, Barcelona-Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; ALT, alanine aminotransferase; AST, aspartate aminotransferase; PLT, platelet count; PT, prothrombin time; others, LDV or LAM in combination with ADV; ALBI, albumin-bilirubin grade = (log10 bilirubin × 0.66) + (albumin × −0.085); ETV, entecavir; TDF, tenofovir; TAF, tenofovir alafenamide fumarate; LDV, telbivudine; LAM, lamivudine; ADV, adefovir.